Psoriasis disease severity measures: Comparing efficacy of treatments for severe psoriasis on ResearchGate, the professional network for scientists. The measurement of psoriasis disease activity in clinical practice is very straightforward. By combining this subjective report with the physician’s global assessment of the severity of the lesions, the physician makes a determination of how severe the disease is and how well the patient is progressing with therapy. Another key measure used in clinical trials of psoriasis is the physician global assessment (PGA; table 3). Radically changing psoriasis measurement in future trials would have the further disadvantage of making it difficult to compare the efficacy of new agents to established agents that had been tested under the previous measurement paradigm. Given the array of treatments for moderate to severe psoriasis and the lack of head-to-head comparative trials, dermatologists and health care insurers face a daunting task in making evidence-based decisions about the selection of treatments. Psoriasis disease severity measures: comparing efficacy of treatments for severe psoriasis.
A large number of clinical measures of psoriasis are used in clinical trials and daily practice. Treatment modalities are chosen on the basis of disease severity, relevant comorbidities, patient preference (including cost and convenience), efficacy, and evaluation of individual patient response 1. Randomized trials comparing the efficacy of narrowband UVB to PUVA have yielded inconsistent findings 68. In a randomized trial (TRANSIT trial) performed in 490 patients with moderate to severe plaque psoriasis who had insufficient responses to methotrexate, measures of the efficacy and safety of ustekinumab after 12 weeks were similar among patients who immediately discontinued methotrexate at the start of ustekinumab therapy and patients who gradually withdrew methotrexate during the first four weeks after starting ustekinumab 152. Standardizing Training for Psoriasis Measures: Effectiveness of an Online Training Video on Psoriasis Area and Severity Index Assessment by Physician and Patient Raters. Results After viewing the training video, PASI-naive physicians produced equivalent scores for all components of PASI; patients provided equivalent scores for most PASI components, with the exception of area scores for moderate-to-severe psoriasis images. Psoriasis patients can score their disease severity with the use of the Self-administered Psoriasis Area and Severity Index, which is the same PASI instrument used by physicians.
The purpose of this study is to compare the safety and efficacy of different doses of etanercept for the treatment of moderate to severe psoriasis. Primary Outcome Measures: Percentage of Participants Achieving a 75 Improvement From Baseline in Psoriasis Area and Severity Index (PASI) Score at Week 24 Time Frame: Week 24 Designated as safety issue: No PASI: Combined assessment of lesion severity and area affected into single score; range: 0(no disease) to 72(maximal disease). PASI: Combined assessment of lesion severity and area affected into single score; range: 0(no disease) to 72(maximal disease). Treatment options for moderate to severe psoriasis include topical and systemic medications, phototherapy, and excimer laser, Combination therapies are often more effective than one treatment alone. The severity of the disease is also measured by its effect on a person’s quality of life. The effectiveness of the treatment is based on a chemical reaction in the skin between the psoralen and light, which creates the redness and inflammation that prevents the psoriasis disease process. More comparison studies are needed to determine risks and benefits compared to NB-UVB, particularly any long-term risk for skin cancer. Assessing Psoriasis Severity and Outcomes for Clinical Trials and Routine Clinical Practice.
How Good Are Clinical Severity And Outcome Measures For Psoriasis?: Quantitative Evaluation In A Systematic Review
Most psoriasis patients are treated with topicals. TNF-blocker, etanercept, in the treatment of plaque psoriasis over 12 weeks. Safe Psoriasis Control (SPC) is an important comprehensive measure that is validated for the assessment of benefit:risk of psoriasis treatments, combining efficacy, quality of life, and safety measures. The objective of this analysis was to assess the benefit:risk of efalizumab, a novel biologic agent indicated for the treatment of moderate-to-severe plaque psoriasis, by applying the SPC to data from randomized, placebo-controlled clinical studies of efalizumab. Despite its shortcomings, the most widely used measure to assess efficacy of new therapies has remained the Psoriasis Area and Severity Index (PASI) 1, 2.